FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

FDA Drug Information Updates by ReachMD

Jan 5, 201800:02:59Health

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ b...

Related Episodes

Continue listening to more episodes from FDA Drug Information Updates.

The FAERS Public Dashboard and its Value to the Pharmaceutical Industry

Jul 31, 2018 - 00:24:45

The FDA has made strides in improving transparency and data access, and has implemented tools to allow th...

FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)

May 4, 2018 - 00:02:59

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures a...

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Jan 7, 2018 - 00:08:29

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the...

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Jan 4, 2018 - 00:03:00

The FDA announced that a review of four large clinical safety trials shows that treating asthma with long...

The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

Oct 29, 2017 - 00:09:22

Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supp...

FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease

Aug 17, 2017 - 00:05:29

FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complicatio...

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Jul 28, 2017 - 00:06:00

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lun...

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Jul 25, 2017 - 00:09:00

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small...